More articles about Clinical Lab Management

The lab will test samples reimbursed only by the federal government. Attis expects it will test a baseline of 3,000 toxicology samples per month by the end of 2018.

Proceeds from the offering could be used to fund acquisitions, to repay existing debts, or for working capital.

Lab, diagnostic and healthcare groups want Congress to enact legislation to modify PAMA and address  concerns about the way CMS collected data and established test prices.

The JV, called ProMedica Pathology Laboratories, will combine the inpatient and outreach testing capabilities as well as esoteric testing capabilities of the partners.

The new robot specimen processing equipment, called WASPLab, is expected to cut labor requirements by 20 percent and reduce test result turnaround time.

By leveraging HealthShare's Informatic Exchange solution, Rhodes Group will create a longitudinal, standardized data repository across TriCore's laboratories.

The company acknowledged the opening up of exclusive insurer contracts may negatively impact revenues next year.

The company's revenue growth resulted from acquisitions, but Quest faced headwinds from PAMA pricing and reductions in hepatitis C genotyping and vitamin D testing.

The system combines proprietary dry slide technology with digital imaging capabilities and the ability to run two separate lab tests simultaneously.

The lab company is beginning to offer the tools and services it used to contain its healthcare spending to health plans and other employers.

The recent OIG report on the implementation of PAMA doesn’t address that CMS has ignored congressional intent in implementing the law, ACLA said.

Improved data capture is expected to help TriCore further develop the analytics that are the basis for the Lab 2.0 model it advocates.

Quest is expected to see incremental volume growth from the UnitedHealthcare contract and from a potential rise in M&A activity with outreach labs.

The PGx decision support software that Sonic is adopting includes clinical reporting for 65 genes and can be tailored to a variety of clinical specialties.

Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.

Through connections with insurers, labs seek to give patients estimates of their financial responsibility for tests at point-of-sale or point-of-order.

Collaborators said that the test is accurate and reliable for the rapid detection of the most common gram-positive bacteria responsible for bloodstream infections.

The trial, part of a multiyear effort to standardize HbA1c testing in labs, will be repeated annually with more labs participating and more countries represented.

The court's ruling that Quest was acting as a licensed healthcare provider could affect the statute of limitations in the suit.

Both recent FDA draft guidance and a new research framework encourage the use of biomarker diagnostics to assess Alzheimer's before symptoms emerge.